Vyxeos Injection Improves Overall Survival in Phase III Acute Myeloid Leukemia Trial

Texas Oncology breaks ground on $120M cancer center in Plano

Texas Oncology on June 4 broke ground on a $120 million cancer center in Plano, marking a milestone for cancer care in North Texas.

June 06, 2025

Vol.51 No.22

Drugs & Targets

Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

Meitheal Pharmaceuticals Inc. on May 29 announced it has launched, through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd., paclitaxel protein-bound particles for injectable suspension (albumin-bound), a generic form of Abraxane, in the U.S.

June 06, 2025

Vol.51 No.22

In Brief

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

On May 30, an international coalition announced the launch of CAR T Vision, a coalition that aims to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy.

May 30, 2025

Vol.51 No.21

In Brief

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

Nadeem R. Abu-RustumLouis Burt NaborsMichael J. StylerJames ThompsonErin HeslerNadeem R. Abu-Rustum, Louis Burt Nabors, Michael J. Styler, and James Thompson were recognized by the National Comprehensive Cancer Network as its 2025 awardees who “go above and beyond to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.”

May 30, 2025

Vol.51 No.21

Drugs & Targets

EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC

The European Medicines Agency approved Calquence (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant.

May 09, 2025

Vol.51 No.18

In Brief

Brian Druker, developer of Gleevec, crosses Boston Marathon finish line alongside daughter Julia

Brian Druker ran the marathon with his daughter, Julia, to celebrate her May 2025 college graduation and law school applications (The Cancer Letter, April 4, 2025).

May 02, 2025

Vol.51 No.17

Vyxeos Injection Improves Overall Survival in Phase III Acute Myeloid Leukemia Trial

YOU MAY BE INTERESTED IN

Texas Oncology breaks ground on $120M cancer center in Plano

Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC

Brian Druker, developer of Gleevec, crosses Boston Marathon finish line alongside daughter Julia

Renew today!

Subscriber content

Never miss an issue!

Login